South Dakota Senate Bill 75, a biosimilar substitution bill, is expected to be signed by South Dakota’s Governor, Dennis Daugaard-R.
In the United States, 9 biosimilars have currently earned FDA approval, with 3 available on the market today. Despite slower biosimilar uptake than originally projected, many states have been introducing legislation for the marketing and potential substitution of biosimilars in preparation for their increased availability and eventual interchangeable status. To date, 37 states and Puerto Rico have passed legislation on biologics and biosimilar substitution, according to the National Conference of State Legislature, with South Dakota becoming the most recent state to have its legislature pass a biologics and biosimilar substitution bill.
South Dakota Senate Bill 75, which is expected to be signed by South Dakota’s Governor, Dennis Daugaard-R, allows pharmacists to substitute an interchangable biosimilar for its reference without the intervention of the prescribing healthcare provider, unless the reference is specifically called for by the prescriber.
However, if a substitution is made, the pharmacist is required to notify the patient when the drug is dispensed (and inform the patient of their right to refuse the biosimilar), and must also notify the prescriber within 5 business days. In addition, the bill requires records of a biologic substitution to be kept either electronically or in hard copy, and provides guidelines for how to label such products (ie, using the product's proper name or brand name).
Senate Bill 75, as well as many other state bills follow the principles endorsed by Biotechnology Innovation Organization (BIO), a biotech industry trade group, which hold that substitution should occur only when the product has the FDA’s interchangeable designation, that prescribers should be able to prevent substitution, that physicians and patients should be notified if substitution occurs, and that good records of substitution must be maintained.
Senate Bill 75 was delivered to Governor Daugaard for signing on February 6.
BIO voiced its support for passage of the bill, saying in a statement that, while almost 90% of the US population is now covered by state laws addressing biosimilar substitution, it “…will keep up the pressure until all 50 states enact this important public policy.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.